<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Shuman, Jill</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Shin, Kichul</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Preventing GC-Induced Bone Loss in Women with RA</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2014-12-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">9-9</style></pages><abstract><style  face="normal" font="default" size="100%">Glucocorticoids (GCs) are a commonly prescribed treatment for patients with rheumatoid arthritis (RA). However, the long-term use of these agents in postmenopausal women is associated with an increased risk of osteoporosis and fracture. Therefore, the prevention of GC-induced osteoporosis has become an important goal in treating women with RA. This article presents data from the now complete randomized, double-blind phase 4 clinical trial, Efficacy of Monthly Ibandronate in Women With RA and Reduced Bone Mineral Density Receiving Long-Term Steroids [NCT01287533]</style></abstract><number><style face="normal" font="default" size="100%">51</style></number><volume><style face="normal" font="default" size="100%">14</style></volume></record></records></xml>